Published in N Engl J Med on September 08, 1994
Preliminary Study of Dornase Alpha to Treat Chest Infections Post Lung Transplant. | NCT01952470
Lung infections associated with cystic fibrosis. Clin Microbiol Rev (2002) 9.20
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med (2011) 8.73
Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev (2012) 4.39
Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol (2001) 4.12
Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One (2012) 3.13
Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest (2012) 3.09
Comparing treatments. BMJ (1995) 3.02
Neutrophil extracellular traps are pathogenic in primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med (2015) 2.80
A purchaser experience of managing new expensive drugs: interferon beta. BMJ (1996) 2.75
Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax (2007) 2.60
Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med (2013) 2.08
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med (2011) 2.04
The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One (2012) 2.03
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med (2014) 1.96
Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. Thorax (2004) 1.86
Nitric oxide metabolites in cystic fibrosis lung disease. Arch Dis Child (1998) 1.76
Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ (2011) 1.74
Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest (2009) 1.73
Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax (1995) 1.72
DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase. Thorax (1995) 1.67
Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros (2011) 1.65
Patient-reported outcomes in cystic fibrosis. Proc Am Thorac Soc (2007) 1.63
Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med (2008) 1.62
Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One (2011) 1.58
Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax (2002) 1.54
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest (2012) 1.53
Inhaled anticoagulation regimens for the treatment of smoke inhalation-associated acute lung injury: a systematic review. Crit Care Med (2014) 1.49
Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros (2011) 1.41
Pyrosequencing Unveils Cystic Fibrosis Lung Microbiome Differences Associated with a Severe Lung Function Decline. PLoS One (2016) 1.39
The clinical value of neutrophil extracellular traps. Med Microbiol Immunol (2009) 1.34
Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. Thorax (2005) 1.31
Phenotypic characterization of clonal and nonclonal Pseudomonas aeruginosa strains isolated from lungs of adults with cystic fibrosis. J Clin Microbiol (2007) 1.29
Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med (2013) 1.20
Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clin Investig (Lond) (2015) 1.13
Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax (2012) 1.12
Pharmacoeconomic analysis in Saudi Arabia: an overdue agenda item for action. Ann Saudi Med (2011) 1.12
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax (2013) 1.12
Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax (2006) 1.11
In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax (1996) 1.09
Long-term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis. Thorax (1998) 1.09
Engineering actin-resistant human DNase I for treatment of cystic fibrosis. Proc Natl Acad Sci U S A (1996) 1.09
Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc (2007) 1.07
Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol (2011) 1.06
Cystic Fibrosis: The Mechanisms of Pathogenesis of an Inherited Lung Disorder. Drug Discov Today Dis Mech (2007) 1.06
Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease. Am J Pathol (1996) 1.06
Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax (2012) 1.04
Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies. Pharmacol Ther (2009) 1.02
Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical review. Health Qual Life Outcomes (2005) 1.02
Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury. Respir Res (2010) 1.00
Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. PLoS One (2012) 0.98
Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation. PLoS One (2013) 0.97
Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob Agents Chemother (2009) 0.97
Exacerbations in cystic fibrosis: 2 . prevention. Thorax (2007) 0.96
Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint. J Cyst Fibros (2010) 0.96
State of progress in treating cystic fibrosis respiratory disease. BMC Med (2012) 0.96
Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Thorax (2006) 0.94
Robust covariate-adjusted log-rank statistics and corresponding sample size formula for recurrent events data. Biometrics (2007) 0.94
Evolution of therapy for cystic fibrosis. N Engl J Med (1994) 0.94
Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol (2012) 0.92
Hypertonic saline in treatment of pulmonary disease in cystic fibrosis. ScientificWorldJournal (2012) 0.92
Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. J Cyst Fibros (2011) 0.92
Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis. J Inflamm Res (2013) 0.91
Cystic fibrosis therapeutics: the road ahead. Chest (2013) 0.91
Respiratory medicine. BMJ (1995) 0.91
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros (2014) 0.91
Gender differences in outcomes of patients with cystic fibrosis. J Womens Health (Larchmt) (2014) 0.91
Targeting bacterial integration host factor to disrupt biofilms associated with cystic fibrosis. J Cyst Fibros (2012) 0.90
Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms. Pediatr Pulmonol (2012) 0.88
DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit Care (2005) 0.88
Chronic rhinovirus infection in an adult with cystic fibrosis. J Clin Microbiol (2013) 0.88
Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis. Drug Des Devel Ther (2013) 0.87
Impact of exacerbations of cystic fibrosis on muscle strength. Respir Res (2013) 0.87
rhDNase in cystic fibrosis. Thorax (1995) 0.87
Clinical trial participants compared with nonparticipants in cystic fibrosis. Am J Respir Crit Care Med (2005) 0.87
New and emerging targeted therapies for cystic fibrosis. BMJ (2016) 0.87
Increased adherence to CFF practice guidelines for pulmonary medications correlates with improved FEV1. Pediatr Pulmonol (2012) 0.87
BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros (2013) 0.86
Human recombinant DNase in cystic fibrosis. J R Soc Med (1995) 0.86
Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. J Pediatr (2013) 0.86
Secretion properties, clearance, and therapy in airway disease. Transl Respir Med (2014) 0.86
Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother (2009) 0.86
Review of recombinant human deoxyribonuclease (rhDNase) in the management of patients with cystic fibrosis. Biologics (2008) 0.86
Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. Br J Clin Pharmacol (2007) 0.86
Children and young adults with CF in the USA have better lung function compared with the UK. Thorax (2014) 0.86
Influence of calcium in extracellular DNA mediated bacterial aggregation and biofilm formation. PLoS One (2014) 0.85
Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann Am Thorac Soc (2014) 0.85
Comparison of WHO and CDC growth charts in predicting pulmonary outcomes in cystic fibrosis. J Pediatr Gastroenterol Nutr (2015) 0.85
Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response. BMC Infect Dis (2015) 0.85
Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps? Proc Am Thorac Soc (2007) 0.84
Changes in cystic fibrosis airway microbial community associated with a severe decline in lung function. PLoS One (2015) 0.84
Phenazine virulence factor binding to extracellular DNA is important for Pseudomonas aeruginosa biofilm formation. Sci Rep (2015) 0.84
A Winogradsky-based culture system shows an association between microbial fermentation and cystic fibrosis exacerbation. ISME J (2015) 0.84
Cystic fibrosis in adults. From researcher to practitioner. West J Med (1996) 0.84
Neutrophil Extracellular Traps in Pulmonary Diseases: Too Much of a Good Thing? Front Immunol (2016) 0.84
The role of the primary care physician in helping adolescent and adult patients improve asthma control. Mayo Clin Proc (2011) 0.84
Cystic fibrosis chronic rhinosinusitis: a comprehensive review. Am J Rhinol Allergy (2013) 0.83
Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention. ISME J (2015) 0.83
Ca2+-dependent activity of human DNase I and its hyperactive variants. Protein Sci (1999) 0.83
Plasma sCD14 as a biomarker to predict pulmonary exacerbations in cystic fibrosis. PLoS One (2014) 0.83
Primary ciliary dyskinesia. Semin Respir Crit Care Med (2015) 0.82
Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol (1984) 6.67
A rapid chemical assay for gentamicin. N Engl J Med (1972) 6.36
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med (1999) 6.23
A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature (1990) 5.42
Haemophilus influenzae meningitis in infant rats after intranasal inoculation. J Infect Dis (1974) 4.94
Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis (2000) 4.93
Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis (1998) 4.82
Production of Haemophilus influenzae b meningitis in infant rats by intraperitoneal inoculation. Infect Immun (1973) 4.80
Innovative communicable disease reporting. HSMHA Health Rep (1971) 4.67
Characterization of non-beta-lactamase-mediated ampicillin resistance in Haemophilus influenzae. Antimicrob Agents Chemother (1984) 4.25
Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature (2000) 4.12
2-Aryl tryptamines: selective high-affinity antagonists for the h5-HT2A receptor. Bioorg Med Chem Lett (2000) 4.03
Evaluation of the culture of safety: survey of clinicians and managers in an academic medical center. Qual Saf Health Care (2003) 3.86
Chronic Lyme borreliosis in the laboratory mouse. Am J Pathol (1993) 3.82
Improved enzymatic assay of chloramphenicol. Clin Chem (1978) 3.31
A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr (2001) 2.78
Hemophilus influenzae type B susceptibility to 17 antibiotics. J Pediatr (1975) 2.74
Lyme borreliosis in genetically resistant and susceptible mice with severe combined immunodeficiency. Am J Trop Med Hyg (1992) 2.71
Elasticity of human lungs in relation to age. J Appl Physiol (1968) 2.47
Gentamicin:adenine mononucleotide transferase: partial purification, characterization, and use in the clinical quantitation of gentamicin. J Infect Dis (1974) 2.45
State of the art: bronchiolitis. Am Rev Respir Dis (1978) 2.41
Rapid detection of chloramphenicol resistance in Haemophilus influenzae. Antimicrob Agents Chemother (1981) 2.41
Failure to detect ampicillin-resistant, non-beta-lactamase-producing Haemophilus influenzae by standard disk susceptibility testing. Antimicrob Agents Chemother (1986) 2.38
Two patients with cystic fibrosis, nonsense mutations in each cystic fibrosis gene, and mild pulmonary disease. N Engl J Med (1990) 2.37
L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry (2000) 2.36
Is the acetylcholine receptor a rabies virus receptor? Science (1982) 2.30
Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia (2008) 2.29
Relative penicillin G resistance in Neisseria meningitidis and reduced affinity of penicillin-binding protein 3. Antimicrob Agents Chemother (1988) 2.28
Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol (2001) 2.24
Nonspecific proliferative responses of murine lymphocytes to Borrelia burgdorferi antigens. J Infect Dis (1992) 2.11
A simplified measurement of respiratory resistance by forced oscillation. J Appl Physiol (1970) 2.11
Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J Pediatr (1994) 2.10
Characterization of chloramphenicol-resistant Haemophilus influenzae. Antimicrob Agents Chemother (1980) 2.07
Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol (1999) 2.05
Studies of the aetiology of neonatal hepatitis and biliary atresia. Arch Dis Child (1977) 2.04
Isolation and assay of rabies serogroup viruses in CER cells. Intervirology (1977) 2.03
The role of encapsulation and host age in the clearance of Haemophilus influenzae bacteremia. J Infect Dis (1977) 2.01
Characterization of Haemophilus influenzae type b fimbriae. Infect Immun (1984) 2.00
Antibiotics and invasive Haemophilus influenzae. N Engl J Med (1976) 2.00
A statewide mass measles immunization program. JAMA (1967) 1.99
Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr (1998) 1.97
Dermatitis as a presenting sign of cystic fibrosis. Arch Dermatol (1992) 1.96
Selective media for the quantitation of bacteria in cystic fibrosis sputum. J Med Microbiol (1984) 1.95
The paradox of Hemophilus infuenzae type B bacteremia in the presence of serum bactericidal activity. J Clin Invest (1976) 1.94
Sepsis and congenital asplenia. J Pediatr (1977) 1.93
T-cell alpha beta + and gamma delta + deficient mice display abnormal but distinct phenotypes toward a natural, widespread infection of the intestinal epithelium. Proc Natl Acad Sci U S A (1996) 1.92
In vitro antibacterial activity of fluorinated analogs of chloramphenicol and thiamphenicol. Antimicrob Agents Chemother (1981) 1.87
Characteristics of 34 adults with psychogenic excoriation. J Clin Psychiatry (1998) 1.86
Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis (1985) 1.85
Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis (1991) 1.84
Identification of common cystic fibrosis mutations in African-Americans with cystic fibrosis increases the detection rate to 75%. Am J Hum Genet (1997) 1.84
Clinical staging in Reye syndrome. Am J Dis Child (1974) 1.84
A permeability barrier as a mechanism of chloramphenicol resistance in Haemophilus influenzae. Antimicrob Agents Chemother (1985) 1.84
Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol (1989) 1.82
Analysis of DNA polymorphism haplotypes linked to the cystic fibrosis locus in North American black and Caucasian families supports the existence of multiple mutations of the cystic fibrosis gene. Am J Hum Genet (1989) 1.81
Isolation of field rabies virus strains in CER and murine neuroblastoma cell cultures. Intervirology (1978) 1.81
Salmonellosis in infants and children. J Pediatr (1967) 1.80
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis (1999) 1.79
Lipid peroxidation by human blood phagocytes. J Clin Invest (1974) 1.79
Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med (2000) 1.78
A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr (1995) 1.75
Riboflavin and mouse hepatic cell structure and function. II. Division of mitochondria during recovery from simple deficiency. J Cell Biol (1969) 1.74
A virulent nonencapsulated Haemophilus influenzae. J Infect Dis (1996) 1.73
A first-generation whole genome-radiation hybrid map spanning the mouse genome. Genome Res (1997) 1.73
Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax (2004) 1.71
Dimensions of the growing trachea related to age and gender. AJR Am J Roentgenol (1986) 1.71
Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J (1995) 1.70
Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest (1996) 1.70
Detection of relatively penicillin G-resistant Neisseria meningitidis by disk susceptibility testing. Antimicrob Agents Chemother (1987) 1.67
Comparative virulence of Haemophilus influenzae with a type b or type d capsule. Infect Immun (1981) 1.66
Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia (2006) 1.66
Role of immunity in the clearance of bacteremia due to Haemophilus influenzae. J Infect Dis (1978) 1.65
Increasing incidence of ampicillin resistance in Hemophilus influenzae. J Pediatr (1978) 1.63
Effect of inoculum size on the susceptibility of Haemophilus influenzae b to beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 1.60
Urogenital, maternal and neonatal isolates of Haemophilus influenzae: identification of unusually virulent serologically non-typable clone families and evidence for a new Haemophilus species. J Gen Microbiol (1990) 1.59
Disposition of drugs in cystic fibrosis. III. Acetaminophen. Clin Pharmacol Ther (1991) 1.59
A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther (2001) 1.58
Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. J Clin Invest (1991) 1.56
End-of-life care in cystic fibrosis. Pediatrics (1997) 1.55
Pigment gallstones form as a composite of bacterial microcolonies and pigment solids. Ann Surg (1987) 1.55
A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest (1991) 1.52
Host cell receptors for two strains of Sindbis virus. Arch Virol (1980) 1.51
In vitro activities and targets of three cephem antibiotics against Haemophilus influenzae. Antimicrob Agents Chemother (1989) 1.49
Characterization of mouse parvovirus infection by in situ hybridization. J Virol (1995) 1.49
Pneumonia and septicemia due to Pseudomonas cepacia in a patient with cystic fibrosis. Johns Hopkins Med J (1980) 1.47
Psychiatric disorders in the first-degree relatives of probands with bulimia nervosa. Am J Psychiatry (1989) 1.46
Diagnosis of Wilson's disease: an experience over three decades. Gut (2000) 1.46
A call for health policy education in the medical school curriculum. JAMA (1995) 1.46
Suppression of airway inflammation by a natural acute infection of the intestinal epithelium. Mucosal Immunol (2008) 1.44
Barbiturate protection in cerebral hypoxia. Anesthesiology (1977) 1.44
Pathogenesis of infection with a virulent allotropic variant of minute virus of mice and regulation by host genotype. Lab Invest (1991) 1.41
Effect of misoprostol on fat malabsorption in cystic fibrosis. Arch Dis Child (1988) 1.41
Group A streptococcal infections of the skin and pharynx (second of two parts). N Engl J Med (1977) 1.39
Angiographic and clinical follow-up of percutaneous revascularization for transplant coronary artery disease. J Invasive Cardiol (2000) 1.39
Effect of chloramphenicol administration in drinking water on predictable steady-state serum concentrations of the drug in mice. Comp Med (2000) 1.39
College of American Pathologists and American Society for Reproductive Medicine accreditation of assisted reproductive technology (ART) laboratories is associated with a decrease in take home baby rates of reporting ART laboratories. Fertil Steril (2000) 1.39
Pharmacokinetics of gentamicin in children and adults. J Infect Dis (1975) 1.39
Laboratory animal medicine in a time of crisis. Comp Med (2001) 1.39